Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function.
In addition to insulin sensitization, the thiazolidenedione drug pioglitazone exhibits favorable circulatory effects. Here, we hypothesized that pioglitazone protects against the hypertension and related vascular derangements caused by the immunosuppressant drug cyclosporine (CSA). Compared with vehicle (olive oil)-treated rats, chronic treatment with CSA (20mg/kg/day s.c., for 14 days) increased blood pressure (BP), reduced the aortic protein expression of phosphorylated eNOS (p-eNOS), and impaired responsiveness of isolated aortas to endothelium-dependent vasorelaxations induced by carbachol. The effects of CSA on BP, aortic p-eNOS, and carbachol relaxations were abolished upon concurrent administration of pioglitazone (2.5mg/kg/day). Serum levels of adiponectin, an adipose tissue-derived adipokine, were not altered by CSA but showed significant elevations in rats treated with pioglitazone or pioglitazone plus CSA. The possibility that alterations in the antioxidant and/or lipid profile contributed to the CSA-pioglitazone BP interaction was investigated. Pioglitazone abrogated the oxidative (aortic superoxide dismutase), lipid peroxidation (aortic malondialdyde), and dyslipidemic (serum LDL levels and LDL/HDL ratio) effects of CSA. Histologically, CSA caused focal disruption in the endothelial lining of the aorta and this effect disappeared in rats co-treated with pioglitazone. Collectively, pioglitazone abrogates the hypertensive effect of CSA via ameliorating detrimental changes in vascular endothelial NOS/NO pathway and oxidative and lipid profiles caused by CSA.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Alexandria, Alexandria, Egypt. mahelm@hotmail.com
Mahmoud M
MM
El-Mas
Hanan M
HM
El-Gowelli
Khaled S
KS
Abd-Elrahman
Evan I
EI
Saad
Abdel-Galil A
AG
Abdel-Galil
Abdel A
AA
Abdel-Rahman
D000818:Animals; D000975:Antioxidants / Q000032:analysis; D001011:Aorta / Q000473:pathology / Q000503:physiopathology; D016572:Cyclosporine / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy*; D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents; D008055:Lipids / Q000032:analysis; D052250:Nitric Oxide Synthase Type III / Q000032:analysis; D000077205:Pioglitazone; D051381:Rats; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use
D000975:Antioxidants; D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents; D008055:Lipids; D045162:Thiazolidinediones; D016572:Cyclosporine; D052250:Nitric Oxide Synthase Type III; C496316:Nos3 protein, rat; D000077205:Pioglitazone